Value proposition

Biopharmaceutical company performing discovery, rational design and initial clinical development of new MLT-based drugs.

Laminar Pharma is a pioneering biopharmaceutical company that focuses on the discovery, rational design and development of a new generation of medicines that act through the innovative therapeutic strategy known as “Membrane-Lipid Therapy” (MLT). Laminar Pharma arose in 2006 as an academic spin-off to commercially develop new scientific know-how and applications generated by leading scientists at the University of the Balearic Islands (UIB) in Mallorca, Spain, headed by Prof. Pablo V. Escriba.

Laminar Pharma aims to develop next-generation medicines, nutraceutical and cosmetic products based on the novel Membrane-Lipid Therapy (MLT) strategy, which targets membrane lipids and/or the structures they form, rather than directly targeting specific cellular proteins. MLT-based drugs specifically interact with and modulate the activity of key signal-transduction peripheral proteins involved in the pathogeny of serious diseases like cancer, CNS, inflammatory or metabolic diseases.

Innovative MLT-based drugs will soon become reference treatments worldwide for serious diseases with important medical needs unmet, such as glioblastoma and other aggressive cancer malignancies, as well as neuro-degenerative, metabolic, cardiovascular or inflammatory diseases. These novel drugs will provide a safe and efficacious therapeutic alternative that will bring dramatic improvements in the clinical outcome and in the quality of life for an important number of patients with these pathologies.

Design, research and development of innovative molecules based on the novel therapeutic approach, the Membrane Lipid Therapy (MLT)